GENOMIC SCORE TO TARGET THERAPY WITH A FIXED DOSE COMBINATION OF HYDRALAZINE AND ISOSORBIDE DINITRATE

被引：0
|
作者：
McNamara, Dennis M. [1 ]
Feldman, Arthur [1 ]
Yancy, Clyde [1 ]
Taylor, Anne [1 ]
Dries, Daniel [1 ]
Hanley-Yanez, Karen [1 ]
Halder, Indrani [1 ]
机构：
[1] Univ Pittsburgh, Pittsburgh, PA USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2016年 / 67卷 / 13期
关键词：
D O I：
10.1016/S0735-1097(16)31354-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1103-083
引用
收藏
页码：1353 / 1353
页数：1
相关论文
共 50 条
  • [1] Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine - The V-HeFT paradox
    Tam, S. William
    Sabolinski, Michael L.
    Worcel, Manuel
    Packer, Milton
    Cohn, Jay N.
    CLINICAL PHARMACOKINETICS, 2007, 46 (10) : 885 - 895
  • [2] Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure
    Angus, DC
    Linde-Zwirble, WT
    Tam, SW
    Ghali, JK
    Sabolinski, ML
    Villagra, VG
    Winkelmayer, WC
    Worcel, M
    CIRCULATION, 2005, 112 (24) : 3745 - 3753
  • [3] Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for black patients with heart failure
    Tam, SW
    Linde-Zwirble, WT
    Worcel, M
    Sabolinski, ML
    Ghali, JK
    Villagra, VG
    Winkelmayer, WC
    Angus, DC
    CIRCULATION, 2005, 112 (17) : U705 - U705
  • [4] Lack of Bioequivalence between Different Formulations of Isosorbide Dinitrate and Hydralazine and the Fixed-Dose Combination of Isosorbide Dinitrate/HydralazineThe V-HeFT Paradox
    S. William Tam
    Michael L. Sabolinski
    Manuel Worcel
    Milton Packer
    Jay N. Cohn
    Clinical Pharmacokinetics, 2007, 46 : 885 - 895
  • [5] Fixed combination isosorbide dinitrate-hydralazine for nitric-oxide-enhancing therapy in heart failure
    Franciosa, Joseph A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (18) : 2521 - 2531
  • [6] The benefits of the fixed-dose combination of isosorbide dinitrate and hydralazine in A-HeFT are not influenced by the absence or presence of diabetes
    Miller, Alan
    Yancy, Clyde W.
    Sabofinski, Michael L.
    Braman, Virginia M.
    Worcel, Manuel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 44A - 44A
  • [7] African American Heart Failure trial: Efficacy of a fixed dose combination of isosorbide dinitrate and hydralazine in heart failure
    Taylor, AL
    Ziesche, S
    Yancy, C
    Carson, P
    D'Agostino, R
    Ferdinand, K
    Taylor, M
    Adams, K
    Sabolinski, M
    Worcel, M
    Cohn, J
    CIRCULATION, 2005, 111 (13) : 1726 - 1726
  • [8] Editorial commentary on fixed combination isosorbide dinitrate/hydralazine for nitric-oxide-enhancing therapy in heart failure
    Flack, John M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (03) : 275 - 277
  • [9] Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure
    Echols, Melvin R.
    Yancy, Clyde W.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (04) : 423 - 431
  • [10] Combination of isosorbide dinitrate and hydralazine in blacks with heart failure
    Taylor, AL
    Ziesche, S
    Yancy, C
    Carson, P
    D'Agostino, R
    Ferdinand, K
    Taylor, M
    Adams, K
    Sabolinski, M
    Worcel, M
    Cohn, JN
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (20): : 2049 - 2057
12345